Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

Have you been paying attention to shares of Corcept Therapeutics (CORT)? Shares have been on the move with the stock up 16.2% over the past month. The stock hit a new 52-week high of $62.98 in the previous session. Corcept Therapeutics has gained 23.6% since the start of the year compared to the -2.1% move for the Zacks Medical sector and the -7.9% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 30, 2024, Corcept reported EPS of $0.41 versus consensus estimate of $0.27 while it beat the consensus revenue estimate by 6.07%.For the current fiscal year, Corcept is expected to post earnings of $1.84 per share on $689.04 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $2.84 per share on $777.04 million in revenues. This represents a year-over-year change of 36.44% and 12.77%, respectively.Valuation MetricsCorcept may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.Corcept has a Value Score of C. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B.In terms of its value breakdown, the stock currently trades at 33.8X current fiscal year EPS estimates, which is a premium to the peer industry average of 20.7X. On a trailing cash flow basis, the stock currently trades at 65X versus its peer group's average of 8X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Corcept currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Corcept meets the list of requirements. Thus, it seems as though Corcept shares could still be poised for more gains ahead.How Does CORT Stack Up to the Competition?Shares of CORT have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is AMNEAL PHARMACEUTICALS, INC. (AMRX). AMRX has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of A, and a Momentum Score of A.Earnings were strong last quarter. AMNEAL PHARMACEUTICALS, INC. beat our consensus estimate by 23.08%, and for the current fiscal year, AMRX is expected to post earnings of $0.70 per share on revenue of $2.77 billion.Shares of AMNEAL PHARMACEUTICALS, INC. have gained 12.2% over the past month, and currently trade at a forward P/E of 12.59X and a P/CF of 6.52X.The Medical - Drugs industry is in the top 35% of all the industries we have in our universe, so it looks like there are some nice tailwinds for CORT and AMRX, even beyond their own solid fundamental situation.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks